PHERGAIN-2

OFFICIAL TITLE: CHEMOTHERAPY-FREE PCR-GUIDED STRATEGY WITH SUBCUTANEOUS TRASTUZUMAB-PERTUZUMAB AND T-DM1 IN HER2-POSITIVE EARLY BREAST CANCER (PHERGAIN-2)

TO BE CONFIRMED.

CLINICAL TRIAL DETAILS

THIS CLINICAL TRIAL EVALUATES THE EFFICACY OF PH FDC SC FOLLOWED BY EITHER CONTINUATION WITH PH FDC SC OR T-DM1 BASED ON INDIVIDUAL PCR AFTER PRE-OPERATIVE TREATMENT, AS ADJUVANT TREATMENT IN NODE-NEGATIVE HER2[+] (IHC3+) EARLY BREAST CANCER PATIENTS BY ASSESSING THE 3-YEAR RECURRENCE-FREE INTERVAL (3Y-RFI).

 

IN ADDITION ASSESS GLOBAL HEALTH STATUS DECLINE RATE AT 1 YEAR FROM START OF NEOADJUVANT TREATMENT.

PHERGAIN-2 AT CLINICALTRIALS.GOV

TUMOR TYPE

PHASE

HER2+ EBC

II

393

70

Spain, France, UK, Italia, Germany

N

SITES

COUNTRY

STATUS

Under Submission

PHERGAIN-2 SITES

home_fondo_you_barra.jpg